BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.

Follistatin (FST), a folliculogenesis regulating protein, is found in relatively high concentrations in female ovarian tissues. FST acts as an antagonist to Activin, which is often elevated in human ovarian carcinoma, and thus may serve as a potential target for therapeutic intervention against ovarian cancer. The breast cancer susceptibility gene 1 (BRCA1) is a known tumor suppressor gene in human breast cancer; however its role in ovarian cancer is not well understood. We performed microarray analysis on human ovarian carcinoma cell line SKOV3 that stably overexpress wild-type BRCA1 and compared with the corresponding empty vector-transfected clones. We found that stable expression of BRCA1 not only stimulates FST secretion but also simultaneously inhibits Activin expression. To determine the physiological importance of this phenomenon, we further investigated the effect of cellular BRCA1 on the FST secretion in immortalized ovarian surface epithelial (IOSE) cells derived from either normal human ovaries or ovaries of an ovarian cancer patient carrying a mutation in BRCA1 gene. Knock-down of BRCA1 in normal IOSE cells demonstrates down-regulation of FST secretion along with the simultaneous up-regulation of Activin expression. Furthermore, knock-down of FST in IOSE cell lines as well as SKOV3 cell line showed significantly reduced cell proliferation and decreased cell migration when compared with the respective controls. Thus, these findings suggest a novel function for BRCA1 as a regulator of FST expression and function in human ovarian cells.

Neutrophils contribute to endotoxin enhancement of allyl alcohol hepatotoxicity.

Nontoxic doses of endotoxin (lipopolysaccharide, LPS) enhance the hepatotoxicity of many xenobiotic agents, including allyl alcohol. Systemic LPS exposure induces an inflammatory response, including accumulation and activation of neutrophils (PMNs) in the liver. The hypothesis that PMNs play a causal role in LPS enhancement of allyl alcohol hepatotoxicity was tested. Rats were pretreated with an anti-neutrophil antibody (anti-PMN immunoglobulin [lg]) to deplete circulating PMNs. Subsequently, they were given LPS or its vehicle, and 2 h later allyl alcohol was administered. The numbers of circulating and hepatic PMNs were decreased in rats pretreated with anti-PMN lg, and liver toxicity induced by cotreatment with LPS and allyl alcohol was attenuated. Treatment with allyl alcohol diminishes the concentration of reduced glutathione (GSH) in liver, raising the possibility that antioxidant defense was compromised in these livers. Accordingly, the hypothesis was tested that allyl alcohol-induced reduction in GSH renders liver cells more sensitive to reactive oxygen species produced by activated PMNs. Isolated hepatocytes were incubated with allyl alcohol in the presence and absence of isolated PMNs stimulated to produce reactive oxygen species. Allyl alcohol produced a concentration-dependent increase in ALT release from hepatocytes. Activated PMNs produced a statistically significant increase in cell killing that was so small it is unlikely to explain the role of PMNs in liver injury in vivo. To test the hypothesis that proteases released from activated PMNs increase the sensitivity of liver cells to allyl alcohol, isolated hepatocytes were incubated with medium from PMNs activated to undergo degranulation. Protease-containing medium from PMNs did not affect allyl alcohol-induced release of ALT from hepatocytes. Taken together, these results indicate that PMNs play a role in the potentiation of allyl alcohol toxicity by LPS. It is unlikely that PMNs contribute to this injury through release of reactive oxygen species or proteases, and other mechanisms must be involved.